Search results
Founder and Chief Strategy Officer. Dr. Mendelsohn is a physician-scientist, research leader and industry executive with broad experience in healthcare. He brings extensive experience as an industry and academic leader in research and development with a focus on molecular and cellular cardiovascular biology.
View Michael Mendelsohn, M.D.’s profile on LinkedIn, a professional community of 1 billion members. Experience: Cardurion Pharmaceuticals · Location: Boston · 500+ connections on LinkedIn.
- 500+
- Cardurion Pharmaceuticals
- 783
- Boston, Massachusetts, United States
Jun 28, 2024 · Mendelsohn has been the executive chairman and president of Cardurion Pharmaceuticals since May 2016 and is the president of the Mendelsohn Consulting Group LLC, which he formed in September 2013.
Nov 30, 2022 · Mendelsohn is a Professor of Medicine at Tufts University School of Medicine. “We are thrilled to add an experienced cardiovascular leader and innovator of Michael’s caliber to our Strategic Advisory Board,” said Christopher Colecchi, Managing Director of Broadview Ventures.
Dr. Mendelsohn brings over 30 years of experience as an academic and industry leader in R&D, as well as expertise as a cardiovascular physician-scientist and as a consultant to leading research efforts for multinational biopharmaceutical companies.
Nov 30, 2022 · BOSTON – November 30, 2022 – Broadview Ventures, a mission-driven, cardiovascular health-focused investment organization, today announced the appointment of Michael E. Mendelsohn, MD to its Strategic Advisory Board.
Founder and Executive Chairman of Cardurion Pharmaceuticals, a cardiovascular biotechnology company. Dr. Mendelsohn also serves currently as senior advisor and consultant to the head of R&D at Takeda Pharmaceuticals and as a Board Director of Foghorn Therapeutics and Broadview Ventures.
